Journal of Dermatological Treatment

Papers
(The H4-Index of Journal of Dermatological Treatment is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Skin type classifications: does the perfect assessment exist?93
Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline – a multivariable regression analysis from the German Pso66
Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Regist63
Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa55
Lessons from a decentralized trial in atopic dermatitis: promises and perils47
A CollaboraTive Initiative of worldwide Vitiligo Experts and patients to define vitiligo activity (ACTIVE): study protocol42
A systematic review of recent randomized controlled trials for palmoplantar pustulosis40
Artificial intelligence-based prescription of personalized scalp cosmetics improved the scalp condition: efficacy results from 100 participants36
Tildrakizumab 200 mg: a step forward in psoriasis treatment with added metabolic benefits35
Correction34
On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies34
Pretreatment Demodex infestation predicts dupilumab-associated blepharoconjunctivitis in atopic dermatitis32
Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)32
Oral propranolol treatment safety in infantile hemangiomas30
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trial30
Ixekizumab-induced interstitial lung disease: a case report confirmed by transbronchial lung cryobiopsy28
Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24–28 and 48–52 weeks28
Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab28
Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial27
Patients’ preferences for systemic treatment of atopic dermatitis: safety and efficacy count the most26
Patient perspective on symptoms of Notalgia paresthetica: subpopulation results from the Neuropathic Itch Patient Survey (NIRVE)25
Topical delgocitinib for the treatment of chronic hand eczema25
Effectiveness and safety of interferon α-2a combined with phototherapy for patients with early-stage mycosis fungoides - a single-arm prospective study in 13 patients25
Impairment in work and activities of daily life in patients with psoriasis: results of the prospective BioCAPTURE registry25
0.63211798667908